An Open-Label Study to Assess the Rate of Failure of an Enbrel® (Etanercept) SureClick™ Auto-injector in Subjects With Rheumatoid Arthritis

An Open-Label Study to Assess the Rate of Failure of an Enbrel® (Etanercept) SureClick™ Auto-injector in Subjects With Rheumatoid Arthritis

An open-label, single arm study to estimate the rate of failure of the Enbrel® SureClick™ Auto-injector in RA subjects.

Inclusion Criteria: - Diagnosis of rheumatoid arthritis

• RA subjects
• 18 years or older
• Currently taking etanercept in pre-filled syringes for at least 4 weeks
• Subjects must give written informed consent
• Subjects must be able to read and write in English Exclusion Criteria: - Subject is not using adequate contraception
• Subject is pregnant or breast feeding
• Significant concurrent medical diseases